Results 251 to 260 of about 463,135 (398)

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

open access: yesAdvanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan   +6 more
wiley   +1 more source

Systematic analysis of structural disorder in the minimal proteome of <i>Mycoplasma pneumoniae</i>. [PDF]

open access: yesMicrobiol Spectr
Pozzoli U   +6 more
europepmc   +1 more source

MTCH2 Deficiency Promotes E2F4/TFRC‐Mediated Ferroptosis and Sensitizes Colorectal Cancer Liver Metastasis to Sorafenib

open access: yesAdvanced Science, EarlyView.
This study identifies MTCH2 as a crucial regulator of ferroptosis in colorectal cancer (CRC) progression. High expression of MTCH2 is correlated with poor prognosis in CRC patients. Furthermore, MTCH2 depletion induces ferroptosis to suppress CRC liver metastasis via the E2F4/TFRC axis and sensitizes tumors to sorafenib treatment, supporting MTCH2 as a
Pu Xing   +18 more
wiley   +1 more source

Comparative analysis of mitochondrial and chloroplast genomes of <i>Dracaena cambodiana</i> from contrasting island habitats. [PDF]

open access: yesFront Plant Sci
Liang H   +10 more
europepmc   +1 more source

Role of Tunneling Nanotubes in Arachidonic Acid Transfer and Macrophage Function Reprogramming in Intrahepatic Cholangiocarcinoma

open access: yesAdvanced Science, EarlyView.
Tunneling nanotubes facilitate the transfer of long‐chain fatty acids, primarily arachidonic acid, from tumor cells to macrophages, leading to lipid accumulation and activation of the PI3K‐Akt pathway. This drives a shift from the anti‐tumor CD5L⁺ phenotype to a pro‐tumor TREM2⁺ phenotype.
Meiru Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy